N
N. Shore
Researcher at University of Alberta
Publications - 16
Citations - 5668
N. Shore is an academic researcher from University of Alberta. The author has contributed to research in topics: Prostate cancer & Enzalutamide. The author has an hindex of 11, co-authored 16 publications receiving 4992 citations.
Papers
More filters
Journal Article
Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.
Crawford Ed,Daniel P. Petrylak,Celestia S. Higano,Adam S. Kibel,Philip W. Kantoff,Eric J. Small,N. Shore,Anna C. Ferrari +7 more
TL;DR: Clinical data to date suggest the optimal timing for sipuleucel-T treatment may be early in the mCRPC treatment paradigm, since the immune response may be more robust when the disease is less advanced and immunosuppressive effects from the tumor or traditional therapies may be less marked.
Journal ArticleDOI
Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC)
David P. Dearnaley,D.R. Saltzstein,J.E. Sylvester,Lawrence Karsh,B.A. Mehlhaff,Christopher Michael Pieczonka,J.L. Bailen,David B. MacLean,S. Sankoh,Hélène M. Faessel,H.M. Lin,N. Shore +11 more
Journal ArticleDOI
2526 Immune responses and clinical data from STRIDE, a randomized, phase 2, open label study of sipuleucel-T with concurrent vs sequential enzalutamide administration in metastatic castrationresistant prostate cancer
Daniel P. Petrylak,David I. Quinn,Robert Dreicer,Emmanuel S. Antonarakis,N. Shore,J.M. Corman,R. Concepcion,Christopher Michael Pieczonka,N. Chang,Todd DeVries,Nadeem A. Sheikh,Charles G. Drake +11 more
Journal ArticleDOI
ATLAS : A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy
Alberto Bossi,David P. Dearnaley,Michael McKenzie,E. Baskin-Bey,R. Tyler,Bertrand Tombal,Stephen J. Freedland,Roach, M. , I I I,Anders Widmark,Adam P. Dicker,Thomas Wiegel,N. Shore,Matthew R. Smith,Margaret K. Yu,Thian Kheoh,Shibu Thomas,Howard M. Sandler +16 more
TL;DR: ATLAS : A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy.